Company: GANX
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001104659-25-068530
Chunk: 1

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 1.01
Chunk 1
---
 (File No. 333-265061) that was initially filed on May 18, 2022, and amended on May 23, 2022, and declared
effective on June 1, 2022 (the “ Registration Statement”) by the Securities and Exchange Commission (the “SEC”)
and a prospectus supplement and accompanying prospectus filed with the SEC.

Pursuant to the Underwriting Agreement, the Company granted to the
Underwriter, an option, exercisable not later than 30 days after the date of the Underwriting Agreement, to purchase from the Company
up to an additional 675,246 shares of Common Stock and/or additional Warrants to purchase up to 337,623 shares of Common Stock, representing
up to fifteen percent (15%) of the shares of Common Stock and Warrants sold in the Offering, for the purpose of covering over-allotments
of such securities, if any.

Pursuant to the terms of the Underwriting Agreement, the Company has
agreed to certain restrictions on the issuance and sale of its Common Stock and securities convertible into shares of Common Stock during
the ninety (90) day period following the date of the Underwriting Agreement.

The Underwriting Agreement contains customary representations, warranties
and agreements by the Company, conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities
under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination
provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such
agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed
upon by the contracting parties.

Upon the closing of the Offering, the Company agreed to issue to
the Underwriter, or its designees, warrants (the “Underwriter’s Warrants”) to purchase up to 315,115 shares
of Common Stock, or 7% of the total number of shares sold in the Offering, or up to an aggregate of 362,382 shares of Common Stock
if the Underwriter exercises in full its option to purchase additional securities. The Underwriter’s Warrants will be
exercisable at an exercise price of $1.94 per share and will be exercisable during the four-and-one-half year period commencing six
months after the date of the Underwriting Agreement. The Underwriter